The CD155/TIGIT axis promotes and maintains immune evasion in neoantigen-expressing pancreatic cancer.
CD155
TIGIT
immune evasion
immunotherapy
pancreatic cancer
Journal
Cancer cell
ISSN: 1878-3686
Titre abrégé: Cancer Cell
Pays: United States
ID NLM: 101130617
Informations de publication
Date de publication:
11 10 2021
11 10 2021
Historique:
received:
11
12
2020
revised:
26
04
2021
accepted:
12
07
2021
pubmed:
7
8
2021
medline:
6
1
2022
entrez:
6
8
2021
Statut:
ppublish
Résumé
The CD155/TIGIT axis can be co-opted during immune evasion in chronic viral infections and cancer. Pancreatic adenocarcinoma (PDAC) is a highly lethal malignancy, and immune-based strategies to combat this disease have been largely unsuccessful to date. We corroborate prior reports that a substantial portion of PDAC harbors predicted high-affinity MHC class I-restricted neoepitopes and extend these findings to advanced/metastatic disease. Using multiple preclinical models of neoantigen-expressing PDAC, we demonstrate that intratumoral neoantigen-specific CD8
Identifiants
pubmed: 34358448
pii: S1535-6108(21)00384-6
doi: 10.1016/j.ccell.2021.07.007
pmc: PMC8511341
mid: NIHMS1730102
pii:
doi:
Substances chimiques
Receptors, Virus
0
poliovirus receptor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1342-1360.e14Subventions
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014051
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009216
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007287
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests T.J. is a member of the Board of Directors of Amgen and Thermo Fisher Scientific, and a co-Founder of Dragonfly Therapeutics and T2 Biosystems. T.J. serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech, and Skyhawk Therapeutics. T.J. is also President of Break Through Cancer. His laboratory currently receives funding from Johnson & Johnson and The Lustgarten Foundation; funds from the Lustgarten Foundation supported the research described in this manuscript. A.R. is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and until August 31, 2020, was an SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and Thermo Fisher Scientific. From August 1, 2020, A.R. is an employee of Genentech, a member of the Roche Group. A.R. and Regev lab members' work was conducted at the Broad Institute, unrelated to these later affiliations. T.D.H., P.D., and J.W.R. are employees and stockholders at NanoString Technologies, Inc. None of these affiliations represent a conflict of interest with respect to the design or execution of this study or interpretation of data presented in this manuscript.
Références
Nat Methods. 2015 Apr;12(4):326-8
pubmed: 25730490
Stem Cell Res. 2019 May;37:101430
pubmed: 30933720
Cancer Discov. 2019 Aug;9(8):1022-1035
pubmed: 31164343
Cancer Immunol Res. 2020 Mar;8(3):409-420
pubmed: 31907209
Nature. 2014 Dec 18;516(7531):428-31
pubmed: 25337879
Nature. 2013 Jul 11;499(7457):214-218
pubmed: 23770567
Cancer Immunol Res. 2015 Apr;3(4):399-411
pubmed: 25678581
Lancet Oncol. 2021 Jan;22(1):118-131
pubmed: 33387490
Nature. 2014 Nov 27;515(7528):577-81
pubmed: 25428507
Nat Methods. 2014 Oct;11(10):1033-6
pubmed: 25128977
Nat Protoc. 2009;4(8):1184-91
pubmed: 19617889
N Engl J Med. 2014 Sep 11;371(11):1039-49
pubmed: 25207767
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Immunity. 2012 Dec 14;37(6):1130-44
pubmed: 23159438
Nature. 2018 Jun;558(7710):454-459
pubmed: 29899446
Clin Cancer Res. 2017 Dec 1;23(23):7263-7275
pubmed: 28947567
Methods Mol Biol. 2013;980:249-66
pubmed: 23359158
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Nat Protoc. 2009;4(11):1670-80
pubmed: 19876027
Genome Med. 2012 Dec 22;4(12):102
pubmed: 23259685
Cancer Discov. 2021 Aug;11(8):2014-2031
pubmed: 33727309
Eur J Immunol. 2003 Oct;33(10):2706-16
pubmed: 14515254
Cell. 1994 Jan 14;76(1):17-27
pubmed: 8287475
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Science. 2015 Dec 11;350(6266):1387-90
pubmed: 26516200
Cell Res. 2020 Apr;30(4):285-299
pubmed: 31974523
Proc Natl Acad Sci U S A. 2020 Apr 7;117(14):8022-8031
pubmed: 32213589
BMC Bioinformatics. 2005 May 31;6:132
pubmed: 15927070
Cell Rep. 2016 Jun 21;15(12):2719-32
pubmed: 27292635
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Cancer Immunol Res. 2017 Nov;5(11):978-991
pubmed: 29066497
Cancer Cell. 2020 Mar 16;37(3):289-307.e9
pubmed: 32183949
Nature. 2019 Aug;572(7770):481-487
pubmed: 31391585
JCI Insight. 2016 Sep 8;1(14):
pubmed: 27642636
Cell. 2020 Oct 29;183(3):818-834.e13
pubmed: 33038342
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Nature. 2017 Nov 23;551(7681):512-516
pubmed: 29132146
N Engl J Med. 2011 May 12;364(19):1817-25
pubmed: 21561347
Immunity. 1996 Oct;5(4):319-30
pubmed: 8885865
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
Cancer Cell. 2012 Jun 12;21(6):822-35
pubmed: 22698406
Nat Immunol. 2009 Jan;10(1):48-57
pubmed: 19011627
Nat Med. 2015 Nov;21(11):1318-25
pubmed: 26479923
Oncoimmunology. 2018 May 24;7(8):e1466769
pubmed: 30221069
JCI Insight. 2019 Mar 21;4(6):
pubmed: 30895946
Cell. 2015 Jan 15;160(1-2):324-38
pubmed: 25557080
J Biol Chem. 2003 Jul 25;278(30):28167-72
pubmed: 12740392
Bioinformatics. 2016 Feb 15;32(4):511-7
pubmed: 26515819
Immunity. 2018 Jul 17;49(1):178-193.e7
pubmed: 29958801
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Cancer Discov. 2018 Sep;8(9):1096-1111
pubmed: 29903880
Bioinformatics. 2016 Apr 15;32(8):1220-2
pubmed: 26647377
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2010-5
pubmed: 21233417
Bioinformatics. 2011 Aug 1;27(15):2156-8
pubmed: 21653522
Cancer Cell. 2018 Apr 9;33(4):563-569
pubmed: 29634944
Elife. 2016 Sep 23;5:
pubmed: 27661255
Immunity. 2016 Aug 16;45(2):389-401
pubmed: 27521269
Cancer Immunol Res. 2019 Mar;7(3):428-442
pubmed: 30642833
J Clin Invest. 2015 Nov 2;125(11):4053-62
pubmed: 26413872
J Gastroenterol. 2020 Jan;55(1):15-26
pubmed: 31494725
Genes Dev. 2000 Apr 15;14(8):994-1004
pubmed: 10783170
Nat Methods. 2017 Jan;14(1):53-56
pubmed: 27869816
Annu Rev Med. 2020 Jan 27;71:47-58
pubmed: 31412220
J Immunol. 2018 Apr 15;200(8):3000-3007
pubmed: 29500245
J Exp Med. 2001 Oct 15;194(8):1151-64
pubmed: 11602643
Nucleic Acids Res. 2019 Jan 8;47(D1):D853-D858
pubmed: 30407534
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
J Exp Med. 2020 Aug 3;217(8):
pubmed: 32453421
J Clin Invest. 2019 Nov 1;129(11):4992-5004
pubmed: 31609250
Nat Genet. 1999 Jan;21(1):70-1
pubmed: 9916792
Nature. 2020 May;581(7806):100-105
pubmed: 32376951
Science. 2015 Apr 3;348(6230):74-80
pubmed: 25838376
Nature. 2019 Oct;574(7780):696-701
pubmed: 31645760
Cell Res. 2019 Sep;29(9):725-738
pubmed: 31273297
J Immunol. 2017 Nov 1;199(9):3360-3368
pubmed: 28978689
Sci Rep. 2016 Feb 18;6:16836
pubmed: 26887506
Cancer Cell. 2017 Aug 14;32(2):185-203.e13
pubmed: 28810144
Immunity. 2016 May 17;44(5):989-1004
pubmed: 27192565
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Neuron. 2010 Nov 18;68(4):695-709
pubmed: 21092859
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Cancer Res. 2001 Dec 15;61(24):8787-93
pubmed: 11751400
Clin Cancer Res. 2017 Apr 1;23(7):1656-1669
pubmed: 28373364
Sci Rep. 2016 Oct 20;6:35848
pubmed: 27762323
Nat Methods. 2018 Aug;15(8):591-594
pubmed: 30013048
Immunity. 2013 Jul 25;39(1):1-10
pubmed: 23890059
Gastroenterology. 2015 Jul;149(1):201-10
pubmed: 25888329
Nat Cancer. 2020 Nov;1(11):1097-1112
pubmed: 34296197
Nat Rev Immunol. 2019 Nov;19(11):665-674
pubmed: 31570879
Cell. 2018 Apr 5;173(2):291-304.e6
pubmed: 29625048
Anticancer Res. 2020 Aug;40(8):4663-4674
pubmed: 32727790
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Genes Dev. 2001 Dec 15;15(24):3243-8
pubmed: 11751630
Annu Rev Immunol. 2004;22:329-60
pubmed: 15032581
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
JAMA Oncol. 2019 Oct 01;5(10):1431-1438
pubmed: 31318392
Br J Cancer. 2019 Jan;120(1):97-108
pubmed: 30377343
Bioinformatics. 2012 Oct 15;28(20):2592-9
pubmed: 22923295
Nat Commun. 2017 Jan 16;8:14049
pubmed: 28091601
Gut. 2014 Nov;63(11):1769-81
pubmed: 24555999
Cell. 2016 Sep 8;166(6):1500-1511.e9
pubmed: 27610572
Brief Bioinform. 2018 Mar 1;19(2):179-187
pubmed: 27802932
Proc Natl Acad Sci U S A. 1984 Apr;81(7):1991-5
pubmed: 6326095
Bioinformatics. 2005 Aug 15;21(16):3439-40
pubmed: 16082012
Nat Methods. 2009 May;6(5):343-5
pubmed: 19363495
Clin Exp Immunol. 2020 May;200(2):108-119
pubmed: 31828774
Nat Methods. 2016 Mar;13(3):241-4
pubmed: 26780092
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140
J Clin Oncol. 2003 Oct 15;21(20):3798-807
pubmed: 12953099
Bioinformatics. 2014 Dec 1;30(23):3310-6
pubmed: 25143287
Genes Dev. 2015 Jul 15;29(14):1576-85
pubmed: 26178787